Cedarburg Hauser Adds Plant Capacity

 

Makes Additional Capital Investments in Response to Demand for Commercial API

Grafton, WI (September 25, 2012) – Cedarburg Hauser Pharmaceuticals (CHP) has expanded the capacity of its Wisconsin based active pharmaceutical ingredient (API) manufacturing plant. The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.

"These improvements increase our total reactor capacity by nearly 50%" says John Flahive, Cedarburg Hauser's newly hired Director of Operations. "We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs."

In addition to the new reactors, Cedarburg Hauser has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities, and upgraded their Emerson DeltaV Digital Automation System.

"The added reactor capacity and upgrades to existing safety and GMP systems are the latest example of Cedarburg Hauser's continued commitment to serving the commercial API marketplace" commented CEO Tony Laughrey. "The flexibility afforded by the additional reactor capacity allows us to better meet our customer's on-time and on-budget requirements" Laughrey continued.  "We will continue to invest in our business as we strive to be the premier contract API manufacturer."

About Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals is an experienced, contract development and manufacturing organization (CDMO), specializing in small molecule active pharmaceutical ingredients (API) and pharmaceutical intermediates. Cedarburg Hauser leverages a talented group of scientists and supporting staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.